The Clinical Impact of the Late Imaging with 18F-Fluorodeoxyglucose PET Texture Analysis in Invasive Lobular Breast Cancer

OBJECTIVE Breast invasive lobular cancer (ILC) is one of the most difficult malignancies to diagnose and follow-up due to its tumor morphology. Tumor heterogeneity is the most important reason for treatment failure and diagnostic limitation. Identification of heterogeneity by a non-invasive method, texture analysis that can be done from positron emission tomography (PET), MR, and CT is developed. In ILC, diagnostic sensitivity is lower with 18F-fluorodeoxyglucose ([18F] FDG) PET/CT compared to invasive ductal carcinoma (IDC). In this study, the correlation between histopathological variables and the texture analysis of [18F] FDG PET/CT standard images, and also late images whose contribution to the diagnosis of many malignancies has been investigated are researched. METHODS Twenty ILC patients underwent standard and late [18F] FDG PET/CT imaging for staging between May 2007 and December 2018. T and N stages, histological and nuclear grades, estrogen receptor, progesterone receptor, human epidermal growth factor-2, and Ki-67 were recorded. RESULTS Thirty-two textural indices with conventional and formal indices and histogram values were calculated with LIFEx software to find heterogeneity in standard and late [18F] FDG PET/CT images. Conventional and discrete indices based on GLRM and GLZM are more correlated than other texture indices. Greater number of significantly correlations was found between histopathological variables and texture analysis of late imaging (p

PDF

___

1. The Lancet. GLOBOCAN 2018: Counting the toll of cancer. Lancet 2018;392(10152):985.
2. Narayan AK, Lehman CD. Mammography screening guideline controversies: Opportunities to improve patient engagement in screening. J Am Coll Radiol 2020;17(5):633–6.
3. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005;93(9):1046–52.
4. Brawley O, Byers T, Chen A, Pignone M, Ransohoff D, Schenk M, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA 2011;306(22):2495–9.
5. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, et al. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer 2008;44(1):73–83.
6. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003;289(11):1421–4.
7. Scheidhauer K, Walter C, Seemann MD. FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions. Eur J Nucl Med Mol Imaging 2004;31(Suppl 1):S70–9.
8. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71(12):3920–5.
9. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31(Suppl 1):S80–7.
10. Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: Microarray and immunohistochemical analysis. J Nucl Med 2010;51(4):543–50.
11. Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, et al. Comparison of 18F-FDG PET/CT for systemic staging of newly diagnosed invasive lobular carcinoma versus invasive ductal carcinoma. J Nucl Med 2015;56(11):1674–80.
12. Dong A, Wang Y, Lu J, Zuo C. Spectrum of the breast lesions with increased 18F-FDG uptake on PET/CT. Clin Nucl Med 2016;41(7):543–57.
13. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20(2):379–87.
14. Jung NY, Kim SH, Kim SH, Seo YY, Oh JK, Choi HS, et al. Effectiveness of breast MRI and (18)F-FDG PET/ CT for the preoperative staging of invasive lobular carcinoma versus ductal carcinoma. J Breast Cancer 2015;18(1):63–72.
15. Choi WH, Yoo IR, O JH, Kim SH, Chung SK. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients. Br J Radiol 2011;84(1003):593–9.
16. Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, et al. Diagnostic accuracy of dual-timepoint 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. Acta Radiol 2012;53(5):518–23.
17. Ozen A, Altinay S, Ekmekcioglu O, Albayrak R, Muhammedoglu A, Yigitbas H, et al. Dual-time (18)FFDG PET/CT imaging in initial locoregional staging of breast carcinoma: Comparison with conventional imaging and pathological prognostic factors. Indian J Surg 2016;78(5):382–9.
18. Moon H, Noh WC, Kim HA, Kim EK, Park KW, Lee SS, et al. The relationship between estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression of breast cancer and the retention index in dual phase (18)F-FDG PET/CT. Nucl Med Mol Imaging 2016;50(3):246–54.
19. Alic L, Niessen WJ, Veenland JF. Quantification of heterogeneity as a biomarker in tumor imaging: A systematic review. PLoS One. 2014;9(10):e110300.
20. Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: A freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 2018;78(16):4786–9.
21. Porter AJ, Evans EB, Foxcroft LM, Simpson PT, Lakhani SR. Mammographic and ultrasound features of invasive lobular carcinoma of the breast. J Med Imaging Radiat Oncol 2014;58(1):1–10.
22. Korhonen T, Kuukasjärvi T, Huhtala H, Alarmo EL, Holli K, Kallioniemi A, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast 2013;22(6):1119–24.
23. Soussan M, Orlhac F, Boubaya M, Zelek L, Ziol M, Eder V, et al. Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. PLoS One 2014;9(4):e94017.
24. Lee JY, Song HS, Choi JH, Hyun CL. Dual-time-point FDG uptake correlates with prognostic factors of invasive breast cancer: Clinical usefulness of early delayed scanning. Diagnostics (Basel) 2019;9(2):40.
25. Garcia-Vicente AM, Pérez-Beteta J, Pérez-García VM, Molina D, Jiménez-Londoño GA, Soriano-Castrejón A, et al. Metabolic tumor burden assessed by dual time point [(18)F]FDG PET/CT in locally advanced breast cancer: Relation with tumor biology. Mol Imaging Biol 2017;19(4):636–44.
26. Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: Investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med 2015;56(1):38–44.
27. Mena E, Sheikhbahaei S, Taghipour M, Jha AK, Vicente E, Xiao J, Subramaniam RM. 18F-FDG PET/ CT metabolic tumor volume and intratumoral heterogeneity in pancreatic adenocarcinomas: Impact of dual-time point and segmentation methods. Clin Nucl Med 2017;42(1):e16–21.
28. Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18FFDG PET: Relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med 2014;55(3):414–22.
29. Bentzon N, Büring M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008;122(5):1089–94.